BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Yoshimura R, Ikenouchi A, Okamoto N, Konishi Y. A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine. Int Med Case Rep J 2021;14:271-3. [PMID: 33953617 DOI: 10.2147/IMCRJ.S306154] [Reference Citation Analysis]
2 Clement A, Pedersen MM, Stensballe A, Wiborg O, Asuni AA. Chronic stress induces NPD-like behavior in APPPS1 and WT mice with subtle differences in gene expression. Genes Brain Behav 2021;:e12766. [PMID: 34382343 DOI: 10.1111/gbb.12766] [Reference Citation Analysis]
3 Sałat K, Furgała-Wojas A. Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic D2/D3 Receptor Agonist, Ropinirole, Attenuate Fibromyalgia-Like Symptoms in Mice. Molecules 2021;26:2398. [PMID: 33924258 DOI: 10.3390/molecules26082398] [Reference Citation Analysis]
4 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Vadodaria KC, Ji Y, Skime M, Paquola A, Nelson T, Hall-Flavin D, Fredlender C, Heard KJ, Deng Y, Le AT, Dave S, Fung L, Li X, Marchetto MC, Weinshilboum R, Gage FH. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry 2019;24:795-807. [PMID: 30700803 DOI: 10.1038/s41380-019-0363-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
6 Yoshimura R, Okamoto N, Konishi Y, Ikenouchi A. Major depression with musical obsession treated with vortioxetine: a case report. Ann Gen Psychiatry 2021;20:19. [PMID: 33750381 DOI: 10.1186/s12991-021-00340-8] [Reference Citation Analysis]
7 Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM. Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research 2019;360:270-8. [DOI: 10.1016/j.bbr.2018.12.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
8 Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol 2017;8:643. [PMID: 28955242 DOI: 10.3389/fphar.2017.00643] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
9 De Berardis D, Fornaro M, Anastasia A, Vellante F, Olivieri L, Rapini G, Serroni N, Orsolini L, Valchera A, Carano A, Tomasetti C, Ventriglio A, Bustini M, Pompili M, Serafini G, Perna G, Iasevoli F, Martinotti G, Di Giannantonio M. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. Braz J Psychiatry 2020;42:317-21. [PMID: 32159712 DOI: 10.1590/1516-4446-2019-0690] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Micov AM, Tomić MA, Todorović MB, Vuković MJ, Pecikoza UB, Jasnic NI, Djordjevic JD, Stepanović-Petrović RM. Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. Prog Neuropsychopharmacol Biol Psychiatry 2020;103:109975. [PMID: 32464241 DOI: 10.1016/j.pnpbp.2020.109975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
11 Piotrowska A, Siwek A, Wolak M, Nowak G. Analysis of Density Changes of Selected Brain Receptors After a 14-Day Supply of Chromium(III) and Evaluation of Chromium(III) Affinity to Selected Receptors and Transporters. Biol Trace Elem Res 2020;196:359-64. [PMID: 31732929 DOI: 10.1007/s12011-019-01924-y] [Reference Citation Analysis]
12 Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep 2017;19:63. [PMID: 28791566 DOI: 10.1007/s11920-017-0816-4] [Cited by in Crossref: 131] [Cited by in F6Publishing: 94] [Article Influence: 32.8] [Reference Citation Analysis]
13 Mlyniec K, Siodłak D, Doboszewska U, Nowak G. GPCR oligomerization as a target for antidepressants: Focus on GPR39. Pharmacol Ther 2021;225:107842. [PMID: 33746052 DOI: 10.1016/j.pharmthera.2021.107842] [Reference Citation Analysis]
14 Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2020;34:506-13. [PMID: 32122230 DOI: 10.1177/0269881120909416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Sharma S, Akundi RS. Mitochondria: A Connecting Link in the Major Depressive Disorder Jigsaw. Curr Neuropharmacol 2019;17:550-62. [PMID: 29512466 DOI: 10.2174/1570159X16666180302120322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
16 Ślifirski G, Król M, Turło J. 5-HT Receptors and the Development of New Antidepressants. Int J Mol Sci 2021;22:9015. [PMID: 34445721 DOI: 10.3390/ijms22169015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
18 Ślifirski G, Król M, Kleps J, Podsadni P, Belka M, Bączek T, Siwek A, Stachowicz K, Szewczyk B, Nowak G, Bojarski A, Kozioł AE, Turło J, Herold F. Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. Eur J Med Chem 2019;180:383-97. [PMID: 31325785 DOI: 10.1016/j.ejmech.2019.07.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
19 Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
20 Maxwell J, Gleason SD, Falcone J, Svensson K, Balcer OM, Li X, Witkin JM. Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia. Behav Brain Res 2019;359:467-73. [PMID: 30471311 DOI: 10.1016/j.bbr.2018.11.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi‐shabestari A, Akhondzadeh S. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double‐blind randomized trial. J Clin Pharm Ther 2020;45:804-11. [DOI: 10.1111/jcpt.13177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 McIntyre RS, Subramaniapillai M, Park C, Zuckerman H, Cao B, Lee Y, Iacobucci M, Nasri F, Fus D, Bowie CR, Tran T, Rosenblat JD, Mansur RB. The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change. Front Psychiatry 2020;11:546. [PMID: 32670103 DOI: 10.3389/fpsyt.2020.00546] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review. Pharmaceuticals (Basel) 2021;14:451. [PMID: 34064611 DOI: 10.3390/ph14050451] [Reference Citation Analysis]
24 Wang Y, Peng M. Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression. Neuropsychiatr Dis Treat 2020;16:3023-33. [PMID: 33324063 DOI: 10.2147/NDT.S282384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Seddighnia A, Tadayon Najafabadi B, Ghamari K, Noorbala AA, Ebrahimi Daryani N, Kashani L, Akhondzadeh S. Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2020;45:97-104. [PMID: 31486103 DOI: 10.1111/jcpt.13032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Cassioli E, Sensi C, Mannucci E, Ricca V, Rotella F. Pharmacological treatment of acute-phase anorexia nervosa: Evidence from randomized controlled trials. J Psychopharmacol 2020;34:864-73. [PMID: 32448045 DOI: 10.1177/0269881120920453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Schanzer B, Rivas-grajales AM, Khan A, Mathew SJ. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opinion on Investigational Drugs 2019;28:1003-12. [DOI: 10.1080/13543784.2019.1680638] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]